Copyright
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Feb 21, 2019; 25(7): 808-823
Published online Feb 21, 2019. doi: 10.3748/wjg.v25.i7.808
Published online Feb 21, 2019. doi: 10.3748/wjg.v25.i7.808
Relationships among KRAS mutation status, expression of RAS pathway signaling molecules, and clinicopathological features and prognosis of patients with colorectal cancer
Xiang-Bin Wan, Jian Cao, Zhi-Chuang Dong, Zhi Li, Department of General Surgery, the Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450008, Henan Province, China
Ai-Qin Wang, Department of Pharmacy, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang 453002, Henan Province, China
Ning Li, Su-Xia Luo, Department of Medical Oncology, the Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450008, Henan Province, China
Sen Yang, China-US (Henan) Hormel Cancer Institute, Zhengzhou 450008, China
Miao-Miao Sun, Department of Pathology, the Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450008, Henan Province, China
Author contributions: Wan XB, Cao J, and Dong ZC collected and analyzed the data; Wan XB drafted the manuscript; Luo SX designed and supervised the study; Wang AQ, Li N, Yang S, Sun MM, and Li Z offered technical or material support; all authors have read and approved the final version to be published.
Supported by the Henan Department of Science and Technology , China, No. 162102310317 .
Institutional review board statement: The study was approved by the Medical Ethics Committee of the Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou, China, and all patients provided written informed consent.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Data sharing statement: No additional data are available.
Open-Access: This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Su-Xia Luo, MD, Professor, Department of Medical Oncology, the Affiliated Tumor Hospital of Zhengzhou University, No. 127, Dongming Road, Jinshui District, Zhengzhou 450008, Henan Province, China. wxbzlyy@126.com
Telephone: +86-371-65961505 Fax: +86-371-65961505
Received: November 14, 2018
Peer-review started: November 14, 2018
First decision: December 5, 2018
Revised: January 17, 2019
Accepted: January 20, 2019
Article in press: January 20, 2019
Published online: February 21, 2019
Processing time: 101 Days and 4.2 Hours
Peer-review started: November 14, 2018
First decision: December 5, 2018
Revised: January 17, 2019
Accepted: January 20, 2019
Article in press: January 20, 2019
Published online: February 21, 2019
Processing time: 101 Days and 4.2 Hours
Core Tip
Core tip: The RAS signaling pathway plays a crucial role in the invasiveness and metastasis of tumor cells. In this study, we examined the relationship between the KRAS gene mutation status and the clinicopathological features and prognosis of colorectal cancer (CRC) patients and the expression of BRAF, MEK, and ERK proteins. We found that KRAS gene mutations do not affect downstream protein expression or the clinicopathological features of CRC. KRAS protein is associated with poor tumor differentiation, older age, and a risk of tumor recurrence. The results may contribute to our understanding of drug resistance in KRAS mutant CRC.